Articles tagged with Breast Cancer
A recent study found that women in states without Medicaid expansion are less likely to receive breast and cervical cancer screenings compared to those in expanding states. The disparity is significant, with uninsured women facing a 7.9% lower rate of mammograms and a 4.9% lower rate of Pap tests.
Researchers have developed nanoparticles carrying siRNA to silence the β3 integrin gene, which regulates cancer cell spread. The treatment significantly inhibited metastasis in mouse models, including five mice with human triple-negative breast cancer.
A new study suggests that background parenchymal enhancement (BPE) on MRI scans may help tailor screening and management strategies to individual breast cancer risk. Women with elevated BPE levels were nine times more likely to be diagnosed with breast cancer, while mammographic density showed no significant relationship.
Research by Cancer Research UK has identified a link between high estrogen levels and an increased risk of male breast cancer. Men with the highest levels of oestrogen were two and a half times more likely to develop breast cancer.
Researchers have discovered a crucial gene, DNMT1, that maintains breast and cancer stem cells. High levels of DNMT1 expression are associated with increased risk of breast cancer, particularly in women over 30. Restoration of the opposing ISL1 gene significantly reduces stem cell populations and cancer growth.
Women with luminal A subtype breast cancer who are older than 60 and taking hormone therapy may not need radiation treatment, according to a new study. The research found that local breast radiation did not add benefit to their outcome, saving the healthcare system up to $3 million annually in Ontario.
A new non-invasive PET scan with C-11-vorozole detects aromatase in all body organs, potentially identifying cancer patients who may benefit from aromatase inhibitor treatment. The study also finds sex-dependent differences in radiation exposure and hormonal status.
Following a healthy lifestyle, including diet and physical activity guidelines, is associated with improved survival when diagnosed with bowel cancer. A large study of over 500,000 participants found that men with a high lifestyle score had a lower risk of mortality, while women who breastfed also showed increased survival.
A new screening method, tomosynthesis, has been found to detect 40% more breast cancers than traditional mammography. The technique uses 3D X-ray images and reduces discomfort and pain during the examination.
Scientists from Houston Methodist report that porous silicon microparticles can potentiate anti-tumor immunity by enhancing cross-presentation and inducing a type I interferon response. This approach shows promise for treating HER2+ breast cancer patients, with potential applications for other types of cancers.
Researchers found that black men under 65 diagnosed with early-stage breast cancer had a 76% higher risk of death than white men, despite similar treatment. The study suggests that poverty may play an important role in racial disparities in breast cancer mortality.
A new study led by UMass Amherst epidemiologist Katherine Reeves is assessing the relationship between phthalate exposure and breast cancer risk. The three-year study will analyze urine samples from 500 women with invasive breast cancer and 1,000 healthy controls to measure levels of 11 phthalate metabolites.
The European Organisation for Research and Treatment of Cancer (EORTC) is part of the CANCER-ID consortium, a €22.7 million project exploring blood-based biomarkers for cancer diagnosis and treatment monitoring.
Breast cancer in young women is characterized by more aggressive disease and increased risk of treatment-related toxicities. Research priorities focus on risk factors, fertility, pregnancy, quality of life, and metastases to improve patient outcomes.
Researchers mapped human genes triggered by soy phytonutrients, revealing a complex role in breast cancer prevention and promotion. Soy flour stimulates tumor-suppressing genes, while purified isoflavones stimulate oncogenes, promoting tumor growth.
A new analysis of the Surveillance, Epidemiology, and End Results (SEER) database found significant variation in health insurance coverage among cancer patients based on demographics and cancer type. Younger, non-White, and rural patients were more likely to be uninsured, while males were less likely than females to have insurance.
Researchers at Women's College Hospital identified a new breast cancer gene, RECQL, strongly linked to the onset of breast cancer in two populations of Polish and French-Canadian women. The study found that specific mutations in the gene were associated with a high risk of developing breast cancer.
Researchers developed an imageable mouse model of brain-metastatic breast cancer and tested a stem-cell-based therapy that eliminates metastatic cells from the brain, prolonging survival. The treatment also prevents negative consequences by targeting tumor-specific molecules.
Researchers found that only 3% of newly diagnosed patients with stage III ILC benefited from systemic staging with FDG PET/CT, suggesting CT and bone scan are sufficient instead.
Scientists have identified 35 genes and three long intervening noncoding RNA molecules that spur aggressive activity in HER2+ breast cancer. These findings provide a new target for treatment approaches, potentially leading to RNA-based therapeutics.
Digital breast tomosynthesis (DBT) increases cancer detection rates among women with dense breasts, with a significant improvement seen in those with dense breasts called back for mass and asymmetry. The study found a striking increase in detection among these groups, offering new insights into DBT's effectiveness.
A new study by Brigham and Women's Hospital finds that breast conserving therapy was successful in over 90% of women who became eligible after treatment with chemotherapy. Despite this, 31% of those eligible chose mastectomy, highlighting the need for further exploration of patient and surgeon factors.
A study found that oophorectomy significantly reduced breast cancer death risk in women with a BRCA1 gene mutation. The procedure also showed promise in reducing all-cause mortality, particularly among estrogen receptor-negative breast cancer patients.
Researchers identified specific genetic markers in African American women with triple negative breast cancer, associated with improved survival rates. The study suggests that these molecular differences may hold the key to improving treatment outcomes for this high-risk population.
The Association for Molecular Pathology compiles current research on liquid biopsy approaches for cancer diagnostics. The review supports the notion that these minimally invasive tests allow for earlier diagnosis, faster and more targeted treatment, reduced costs, and increased quality of life.
Most breast and general surgeons still advocate for annual mammography starting at age 40, despite a 2009 USPSTF recommendation to screen biennially from 50 to 74. Researchers found 88% of breast surgeons and 82% of general surgeons recommend annual screenings.
A new study confirms that moderate coffee consumption reduces breast cancer recurrence risk in women treated with tamoxifen. The study found that caffeine and caffeic acid in coffee inhibit tumor growth and cell division.
Researchers have tested an experimental immune system drug, MPDL3280A, in a preliminary human study and found it to be generally safe and well-tolerated. The therapy aims to restore the immune system's ability to recognize and attack cancer cells, with promising results in controlling disease in some patients.
Researchers at Cold Spring Harbor Laboratory have identified a previously unknown signaling pathway in HER2-positive breast cancer cells. The pathway involves protein tyrosine phosphatase PTPD2, which regulates abnormal cell growth when the HER2 pathway is activated.
A collaborative study by the University of Colorado Cancer Center and National Cancer Institute reports TERT gene promoter alterations in 69% of bladder cancers. The study suggests these alterations may be an early precursor to the disease and could lead to genetic testing for screening.
A comprehensive analysis confirms biennial mammography screening offers a favorable balance of benefits to harm for women ages 50-74 with an average risk of developing breast cancer. Screening strategies, including starting age and interval between exams, are analyzed to determine the optimal approach.
Researchers found that overnight fasting reduced postprandial glucose levels and associated them with lower breast cancer risk. Longer nighttime fasts were linked to fewer calories consumed per day and improved biomarker results.
Researchers develop a new drug combination that targets both estrogen-sensitive cells and cancer stem cells causing treatment resistance in breast cancer. The therapy combines Evgen's Wnt pathway-suppressing drug Sulforadex with standard hormonal treatments.
Breast cancer cells can survive detachment from the extracellular matrix by forming multicellular aggregates, stabilizing EGFR protein. Elevated Bim-EL protein in inflammatory breast cancer cells blocks anoikis through complex with Beclin-1 and LC8.
A new study by Women's College Hospital and ICES confirms a strong link between ethnicity and breast cancer stage at diagnosis for Canadian women. South Asian women are more likely to be diagnosed with later stage breast cancer compared to the general population.
Researchers discovered a molecular mechanism connecting breast tissue stiffness to tumor metastasis and poor prognosis. High stiffness causes TWIST1 protein to lose its anchor, enabling cancer cells to invade surrounding tissue and metastasize.
A gene expression model called COXEN predicts canine osteosarcoma response to doxorubicin, potentially allowing veterinary oncologists to choose the most effective drug. The approach validates human models used to predict drug response in clinical trials.
Researchers found that long-time consumption of soyfoods boosts immune response against breast tumors, reducing cancer recurrence. Genistein in soyfoods activates anti-tumor immune responses and reduces immunosuppressive mechanisms.
African-American women with ER+ breast cancer experience poorer outcomes due to increased activation of the unfolded protein response (UPR) pathway, reducing sensitivity to tamoxifen treatment. Strategies targeting this pathway could improve therapy effectiveness.
A new study by Ludwig-Maximilians-Universität München attributes mild cognitive defects in breast cancer patients to post-traumatic stress induced by diagnosis, not chemotherapy side-effects. The study found pretreatment cognitive impairment in breast cancer patients was due to stress associated with the disease.
Researchers analyzed over 12,000 proteins in triple-negative breast cancer cells, identifying subtypes and correlations with drug response. The findings suggest that treatments targeting cell spread may be effective against resistant tumors.
A new study found that cancer-related post-traumatic stress is associated with very limited cognitive impairment before treatment among newly diagnosed breast cancer patients. The study, published in the JNCI Journal of the National Cancer Institute, analyzed data from 166 breast cancer patients and 60 matched controls.
Researchers discovered that myeloid cells switch roles and become anti-therapy agents when angiogenesis inhibitors are used, leading to tumor growth and relapse. Targeting the PI3K signaling pathway may offer a way to prevent this phenomenon.
Analysis of two Women's Health Initiative clinical trials reveals a pattern of changing influences on breast cancer incidence over time, with estrogen plus progestin use linked to increased risk and estrogen alone showing reduced risk. The study suggests that ongoing influences after stopping hormone therapy require recalibration of br...
A new blood test has been developed to predict future breast cancer by analyzing metabolic profiles of over 57,000 people. The test shows a sensitivity of 80% in predicting the likelihood of developing breast cancer within two to five years.
A study by University of Manchester researchers has identified four subtypes of ductal carcinoma in situ (DCIS) that relate to disease recurrence. Patients with certain tumour characteristics, such as oestrogen receptor and progesterone receptor positivity, are less likely to experience cancer progression, while others are at higher risk.
Researchers validated a previously reported molecular finding on triple negative breast cancer, but found it was limited to a single patient and could not be applied to further clinical work. The study highlights the importance of independent study validation and careful assay development.
A recent study suggests that genetic testing for BRCA1 and BRCA2 mutations in women with ovarian cancer can help identify carriers and reduce their risk. The study found that 19% of women with the most common form of ovarian cancer carry these mutations, which is higher than previous estimates.
A study suggests that sequencing tumor genomes without comparing them to a patient's noncancerous tissue can lead to inaccurate treatment decisions and side effects. The researchers analyzed over 800 cancer patients' data, finding that nearly half of the identified genetic changes were not related to the cancer.
PharmaMar is presenting data on its anticancer candidates PM1183 and plitidepsin, showing synergistic effects against breast cancer cell lines and SCLC mouse tumor models. The company's studies also highlight the potential of plitidepsin as a novel therapeutic target in multiple myeloma.
A study has identified a molecular signature that drives the growth and survival of triple negative breast cancer cells. The research reveals that high levels of Myc protein and low levels of TXNIP correlate with poor patient outcomes.
Researchers at Cold Spring Harbor Laboratory have discovered that tumor cells can form tubular networks resembling blood vessels, facilitating metastasis in breast cancer. This phenomenon, known as vascular mimicry, allows tumor cells to access the bloodstream and colonize new sites.
A study by Professor Rama Khokha found that genetically modified mice without TIMP1 and TIMP3 experienced youthful breast tissue, with stem cells remaining functional throughout their lifetime. The results challenge the assumption that large numbers of stem cells increase cancer risk.
A test for 77 genetic risk factors showed a significant link between a woman's polygenic risk score and her breast cancer risk, with those in the top 20% being 1.8 times more likely to develop breast cancer than average women.
A study of over 31,000 women with BRCA1 and BRCA2 mutations found that the risk of breast and ovarian cancer varies by mutation type. The findings suggest that knowledge of mutation-specific risks could inform clinical decision-making among carriers.
Researchers found that specific BRCA mutations are linked to higher breast cancer risk and lower ovarian cancer risk, potentially leading to more personalized risk assessment and prevention strategies. The study analyzed data from over 31,000 women with BRCA1 or BRCA2 gene mutations.
A Yale University study found that higher breast cancer treatment costs are associated with better survival rates. Over a decade, Medicare costs increased from $18,100 to $32,600, while five-year survival improved from 38.5% to 51.9%. The cost increase was largely due to chemotherapy and radiation therapy.
A third of breast cancer patients report strong desire for genetic testing but many do not receive relevant discussions with healthcare professionals. This study highlights the unmet need for addressing genetic risk in these patients.
A Mayo Clinic-led team has combined 77 common genetic variants into a polygenic risk score to improve breast cancer identification. The score is associated with a higher or lower risk of developing breast cancer, and can be used in conjunction with traditional predictors to personalize estimates.
The 14th St. Gallen International Breast Cancer Consensus Conference highlighted the need to refine breast cancer classification and predict treatment responses. The conference recommendations will set the standard for breast cancer care for two years, taking into account variable resource limitations worldwide.